Telix Pharmaceuticals has signed an agreement to acquire 100% of ITM Isotope Technologies Munich in a transaction carrying $1.65 billion of upfront consideration and as much as $700 million of additional milestone payments, potentially bringing the total consideration to $2.35 billion.
The combination brings together Telix’s precision medicine and radiopharmaceutical development platform with ITM’s large-scale radioisotope manufacturing business, global distribution network and late-stage therapeutic pipeline.
Telix said the transaction is a major step in its strategy to become a more vertically integrated radiopharmaceutical company with capabilities spanning drug development, isotope production, manufacturing and commercialization.
Munich-based ITM was founded in 2004 and has built a commercial-scale radioisotope manufacturing and distribution network serving more than 65 countries.
The company produces therapeutic radioisotopes including lutetium-177, actinium-225 and terbium-161. Telix described ITM as the only producer of globally scaled commercial-grade lutetium-177 and a key supplier for both marketed and investigational radiopharmaceutical therapies.
ITM generated $273 million in revenue during 2025 after recording a compound annual growth rate of approximately 40% between 2021 and 2025.
Its manufacturing operation is profitable and cash-generating, providing Telix with an established commercial business as well as greater control over supplies of isotopes required for its own therapeutic pipeline.
The combined organization is expected to generate more than $1.3 billion of unaudited pro forma 2026 revenue and income based on management estimates.
Telix expects growth in the isotope manufacturing business, cost savings, additional synergies and pipeline optimization to support a positive EBITDA contribution from the combination beginning in 2027, excluding one-time implementation costs and subject to the realization of the company’s assumptions.
Beyond manufacturing, the deal significantly expands Telix’s therapeutic pipeline.
One of ITM’s most important assets is ITM-11, or lutetium-177 edotreotide, an investigational targeted radionuclide therapy being developed for gastroenteropancreatic neuroendocrine tumors, or GEP-NETs.
ITM-11 targets somatostatin receptors expressed by certain neuroendocrine tumors and has successfully completed the Phase 3 COMPETE study.
A second Phase 3 trial, COMPOSE, is fully enrolled and is evaluating the therapy in an expanded patient population. An interim analysis is expected during the first half of 2027.
If approved, ITM-11 could give Telix a near-term route into the commercial therapeutic radiopharmaceutical market while expanding its presence beyond its existing precision medicine operations.
The company also sees a sizable long-term opportunity as demand for nuclear medicine expands. The global nuclear medicine market is forecast to reach approximately $41 billion by 2034, according to industry research cited by Telix.
Under the deal terms, Telix will acquire ITM for $1.65 billion upfront on a cash-free and debt-free basis.
Approximately $1.25 billion is expected to be paid to ITM sellers through 105.8 million newly issued Telix shares priced at $11.84 per share, based on Telix’s 30-day trailing volume-weighted average price before signing.
Those shares will ultimately be released to the sellers as Nasdaq-listed American depositary receipts following applicable escrow periods.
Telix will also assume approximately $302 million of ITM net debt at closing.
Another approximately $96 million reflects management equity rollover and transaction expenses payable by the sellers, subject to closing adjustments.
The deal also includes up to $700 million of contingent consideration tied primarily to regulatory approvals and commercial performance of ITM-11.
As much as $250 million is connected to U.S. Food and Drug Administration approvals across three indications.
Telix would pay $100 million if ITM-11 receives FDA approval for G1-G2 GEP-NETs by December 31, 2027, another $100 million for approval in G2-G3 GEP-NETs by December 31, 2030, and $50 million for a lung neuroendocrine tumor indication by December 31, 2031.
Another $450 million could become payable based on ITM-11’s global net sales during fiscal 2030 exceeding $150 million.
Telix can elect to settle milestone consideration in cash or shares, subject to shareholder approvals associated with potential share issuance.
The transaction will also significantly change Telix’s ownership structure.
Following completion, existing Telix shareholders are expected to own approximately 76.3% of the combined company’s outstanding shares, while former ITM shareholders will hold approximately 23.7%.
Telix’s board has approved the agreement, and shareholders representing more than 90% of ITM’s shares had approved the transaction as of signing.
The acquisition remains subject to Telix shareholder approval under ASX listing requirements, regulatory clearances and customary closing conditions.
Telix expects the transaction to close by the end of fiscal 2026, with an extraordinary shareholder meeting expected in November.
For Telix, the strategic significance extends beyond adding another drug candidate.
Radiopharmaceutical companies depend on specialized radioactive isotopes that can be difficult to manufacture, transport and deliver because of short half-lives and complex regulatory requirements.
Owning a major isotope manufacturer therefore gives Telix greater control over an important part of its supply chain while adding a business that already supplies other companies across the sector.
The merger also gives ITM access to Telix’s commercial precision medicine infrastructure and broader development organization as its therapeutic programs move toward potential commercialization.
Together, the companies expect to create a radiopharmaceutical platform spanning isotope production, global distribution, clinical development, manufacturing and commercialization while maintaining a large pipeline of therapeutic candidates.
KEY QUOTES:
“This merger positions Telix at the forefront of the consolidation that is occurring as the industry matures. ITM is the leader in radioisotope production, with deep scientific expertise and a track record of value-adding innovation.”
“By combining our complementary strengths, we will create a company with commercial scale, world-leading supply and the most exciting theranostic drug portfolio in the sector.”
Dr. Christian Behrenbruch, Managing Director and Group CEO of Telix Pharmaceuticals
“Joining two radiopharmaceutical pioneers creates a company with unmatched breadth and depth across the value chain, supported by deep expertise and talent.”
“Together, we believe Telix and ITM will be uniquely positioned to capitalize on rapidly growing global demand for radiopharmaceuticals to the benefit of both Shareholders and patients.”
Dr. Andrew Cavey, CEO of ITM Isotope Technologies Munich
